HemaCare and Zenbio Leverage Cryogenic Logistics Technology, Eliminate Cell Degradation Threat

By CIOReview | Friday, August 7, 2015

 LAKE FOREST, CA: Medical logistics is the delicate process to be handled with care as it involves transportation of sensitive products. Cryogenic logistics solutions provider for life science industries, Cryoport will endow its proprietary packaging and cold chain logistic services to HemaCare which delivers human-derived primary cells and tissues for biomedical research and to Zenbio- a distributor of cell based products and contract services across biotechnology industry.

Cryoport’s Cryportal Express, a patented liquid nitrogen dry-vapor shippers transport biomedical materials like stem cells, reproductive cells and immunotherapies to pharmaceutical companies, laboratories and university researchers. The Cryport solution replaces dry ice virtually to maintain stable temperatures and eliminate the threat of cell degradation during frozen transportation. The Cryportal governs and manages documentation process for secure transportation. In addition Cryport offers affordable packaging and transport costs along with non-toxic dry vapor technology that utilizes eco-friendly materials.

 HemaCare Bioresearch Products and Services provide mobilized peripheral blood, bone marrow and cord blood for enhanced lab research; also supports cell therapy clinical trials and consulting services in quality and regulatory compliance. Through Cryport partnership it will have access to Cryport’s cold chain logistics for extended range of functional cell and tissue samples, achieving accurate research outcomes.

Similarly, in order to develop human conditions, ZenBio serves cell-driven solutions to elevate innovation in therapies. It other offerings include contract research services for outsourcing key projects, custom consultations, cell characterization, molecular biology services and research solutions platform. Recently ZenBio initiated to substitute Bovine-derived products with Human Serum. Now Cryport will support ZenBio to administer Human Platelet Lysate and an array of cell-based solutions for discovery of regenerative therapies.

Peter Pieraccini, CEO, ZenBio, says, “Our team is able to focus on the development of new products for the marketplace when we are in the hands of a reliable distribution partner. Cryoport is a significant asset for our team to leverage in our distribution strategies worldwide."